Published in J Clin Oncol on May 01, 1995
Curing metastatic testicular cancer. Proc Natl Acad Sci U S A (2002) 1.92
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol (2008) 1.63
Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer (2006) 1.17
Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology (2008) 1.13
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer (2005) 1.06
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer (1999) 1.06
Late relapse of testicular cancer. World J Urol (2004) 1.03
Cervical mature teratoma 17 years after initial treatment of testicular teratocarcinoma: report of a late relapse. World J Surg Oncol (2007) 0.97
Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J (2010) 0.92
Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer (2010) 0.84
Management of poor-prognosis testicular germ cell tumors. Indian J Urol (2010) 0.83
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematol Oncol Clin North Am (2011) 0.82
Late recurrence and second primary malignancy among 139 patients with germ cell tumors: long-term outcome of the disease in a single-center experience. Jpn J Clin Oncol (2009) 0.82
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol (2014) 0.82
Contemporary lymph node counts during primary retroperitoneal lymph node dissection. Urology (2010) 0.81
The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol (2009) 0.80
Management of the post chemotherapy subcentimeter residual mass: the case for observation. World J Urol (2009) 0.80
Reoperative retroperitoneal lymph-node dissection for testicular germ cell tumor. World J Urol (2009) 0.79
Laparoscopic resection of a residual retroperitoneal tumor mass of nonseminomatous testicular germ cell tumors. Surg Endosc (2011) 0.78
Prepubertal Testicular Tumors in Korea: A Single Surgeon's Experience of More Than 20 Years. Korean J Urol (2013) 0.78
Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor. Indian J Urol (2010) 0.78
Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT). Br J Cancer (2000) 0.78
Late relapse of germ cell tumors. World J Urol (2009) 0.78
Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. Br J Cancer (1996) 0.77
Laparoscopic retroperitoneal lymph node dissection for stage I and II nonseminomatous germ-cell tumors. Ther Adv Urol (2009) 0.77
Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. Open Access J Urol (2011) 0.76
Rapid Identification of Chemoresistance Mechanisms Using Yeast DNA Mismatch Repair Mutants. G3 (Bethesda) (2015) 0.76
Advances in the treatment of testicular cancer. Transl Androl Urol (2015) 0.75
Very late relapse of testicular tumour in combination with renal cancer and their retroperitoneoscopic removal. Case Rep Med (2011) 0.75
Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies. Indian J Urol (2010) 0.75
Osteolytic bone destruction resulting from relapse of a testicular tumour 23 years after inguinal orchiectomy and adjuvant chemotherapy: a case report. J Med Case Rep (2009) 0.75
Late Relapse and Follow-up Protocols in Testicular Germ Cell Tumours: The Edinburgh Cancer Centre Experience and Review of the Literature. Clin Med Oncol (2008) 0.75
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report. Oncol Lett (2014) 0.75
Metastasectomy as optimal treatment for late relapsing solitary brain metastasis from testicular germ cell tumor: a case report. BMC Res Notes (2014) 0.75
Current Concepts in Management of Stage I NSGCT. Indian J Surg Oncol (2016) 0.75
Isolated late metastasis from testicular seminoma presenting as a parotid gland mass: case report and review of the literature. Curr Oncol (2013) 0.75
Cutaneous metastasis from testicular germ cell tumour. Indian J Urol (2014) 0.75
Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience. World J Urol (2004) 0.75
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med (1977) 4.91
Drugs five years later. Cisplatin. Ann Intern Med (1984) 3.69
Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol (1996) 3.59
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med (1987) 3.52
Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med (1997) 3.48
Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med (1993) 3.25
Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J Immunol (1999) 3.21
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol (2001) 3.06
Breast self-examination practices and breast-cancer stage. N Engl J Med (1978) 3.03
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1992) 2.90
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2000) 2.73
Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med (1990) 2.64
Adverse relationship between blood transfusions and survival after colectomy for colon cancer. Cancer (1985) 2.24
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. Semin Oncol (1979) 1.91
The development of non-germ cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases. Cancer (1984) 1.85
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol (1992) 1.84
Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol (1997) 1.81
Breast self-examination practices and breast cancer survival. Cancer (1984) 1.81
Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer (1980) 1.79
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol (1996) 1.77
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer (2006) 1.77
Hemopoietic progenitor cells of W anemic mice studies in vivo and in vitro. J Cell Physiol (1968) 1.74
Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest (1991) 1.72
Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol (1998) 1.72
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1997) 1.70
Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol (1997) 1.70
Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol (1989) 1.68
Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg (1994) 1.65
Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res (2001) 1.64
Primitive neuroectodermal tumors arising in testicular germ cell neoplasms. Am J Surg Pathol (1997) 1.64
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol (1995) 1.60
Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol (1999) 1.59
Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res (1999) 1.58
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med (1979) 1.57
Tumors of the small intestine. World J Surg (2000) 1.54
Decreased liver and lung drug-metabolizing activity in mice treated with Corynebacterium parvum. Cancer Res (1976) 1.53
Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol (1994) 1.51
Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol (1993) 1.51
Adrenalectomy via the dorsal approach: a benchmark for laparoscopic adrenalectomy. J Urol (1995) 1.50
Legionnaires' disease in patients with associated serious disease. Ann Intern Med (1979) 1.50
Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol (1988) 1.49
Splenic rupture during occlusion of the porta hepatis in resection of tumors with vena caval extension. J Urol (1994) 1.48
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol (1991) 1.47
Metastatic patterns of choroidal melanoma. Cancer (1974) 1.45
Tumors of the esophagus. World J Surg (2000) 1.44
Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur J Cancer (2000) 1.42
Cholinergic and adrenergic interactions in the thermoregulatory centers of the rat. Brain Res (1969) 1.41
Prevalence of acne keloidalis nuchae in football players. J Am Acad Dermatol (1997) 1.41
Advanced testicular cancer: update for urologists. J Urol (1998) 1.41
Hematologic malignancies associated with primary mediastinal germ-cell tumors. Ann Intern Med (1985) 1.41
Defining new standards for adjuvant therapy of testis cancer. J Clin Oncol (1995) 1.39
Dosimetry of swallowed non absorbed 99mTc radiopharmaceuticals in pediatric patients. Eur J Nucl Med (1990) 1.39
Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol (1994) 1.39
The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. J Urol (1995) 1.39
Effect of breathing on the detection of in vivo simulated pulmonary nodules by spiral CT. Clin Radiol (1998) 1.38
Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res (1981) 1.37
The value of cost projections. Health Aff (Millwood) (1995) 1.37
Improved chemotherapy in disseminated testicular cancer. J Urol (1977) 1.37
Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer (1978) 1.35
Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis (1994) 1.34
Blood transfusions and survival after lung cancer resection. Am J Surg (1985) 1.33
Fine needle aspiration of the breast. Importance of the aspirator. Acta Cytol (1987) 1.33
Fertility after chemotherapy for testicular cancer. J Clin Oncol (1983) 1.32
The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med (2001) 1.30
The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol (2000) 1.30
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med (1987) 1.30
Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol (1993) 1.29
Distribution of nodal metastases in nonseminomatous testis cancer. J Urol (1982) 1.29
Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis (1992) 1.27
Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol (1997) 1.26
Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med (1979) 1.26
Core-cutting needle biopsy for the diagnosis of breast cancer. Am J Surg (1982) 1.25
Testicular cancer: the quest continues. J Natl Cancer Inst (1988) 1.25
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res (1974) 1.25
Tumors of the rectum and anal canal. World J Surg (2000) 1.24
Bilateral testicular tumors: management and outcome in 21 patients. Cancer (1998) 1.23
Mangement of infantile esotropia. Am J Ophthalmol (1976) 1.23
Electrophoretic comparison of endonuclease-digested plasmids from Neisseria gonorrhoeae. J Bacteriol (1976) 1.23
Germ cell tumor associated primitive neuroectodermal tumors. J Urol (2001) 1.23
Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol (1991) 1.22
Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol (1988) 1.22
The role of maintenance therapy in disseminated testicular cancer. N Engl J Med (1981) 1.22